Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

28.940
+0.2000.70%
Volume:6.23M
Turnover:181.50M
Market Cap:10.24B
PE:-32.52
High:29.960
Open:29.620
Low:28.540
Close:28.740
52wk High:58.450
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:2.53
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.67
PE(LYR):-32.52
PS:3.63

Loading ...

Movement Alert|EVEREST MED Falls 5.39% in Regular Trading, Haisen Strategic Cooperation Raises Related-Party Transaction Concerns Amid Continued Profit-Taking

Market Focus
·
Sep 11

Movement Alert|EVEREST MED Falls 5.38% in Regular Trading, Post-Approval Profit-Taking on Xingbituo Continues Amid Sector Weakness

Market Focus
·
Sep 10

Everest Medicines Unit Enters Supply, Distribution Cooperation Contract

MT Newswires Live
·
Sep 09

Everest Medicines seals strategic cooperation with Hasten; sets RMB3.08 billion 2028 cap on connected transactions

Bulletin Express
·
Sep 09

Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion

Stock News
·
Sep 09

Movement Alert|EVEREST MED Falls 5.02% in Regular Trading, Post-Approval Rally Fades as Xingbituo PSVT Milestone Fully Priced In

Market Focus
·
Sep 09

Hong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication

Stock News
·
Sep 08

Movement Alert|EVEREST MED Rises 5.05% in Regular Trading, First Cardiovascular Drug Star Bi Tuo Approved by NMPA

Market Focus
·
Sep 08

Everest Med Lifts Issued Share Count to 354.08 Million in August on Option Exercises

Bulletin Express
·
Sep 04

Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co

Reuters
·
Sep 03

Everest Medicines Gets China Nod for CARDAMYST Application

MT Newswires Live
·
Sep 03

EVEREST MED Wins NMPA Approval for CARDAMYST Nasal Spray, First Self-Administered Treatment for Adult PSVT in China

Bulletin Express
·
Sep 03

Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults

Reuters
·
Sep 03

Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China

THOMSON REUTERS
·
Sep 03

EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT

Stock News
·
Sep 03

Movement Alert|EVEREST MED Rises 6.56% in Regular Trading, Rebounding After Recent Profit-Taking as mRNA Biotech Sector Recovers

Market Focus
·
Sep 02

Movement Alert|EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares

Market Focus
·
Aug 31

Movement Alert|EVEREST MED Falls 5.2% in Regular Trading, mRNA Concept Sentiment Cooling and Sector Weakness Trigger Pullback

Market Focus
·
Aug 28

Movement Alert|EVEREST MED Rises 5.16% in Regular Trading, mRNA Momentum and Strong Earnings Continue to Fuel Rally

Market Focus
·
Aug 26

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25